By Kosaku Narioka
Takeda Pharmaceutical is scheduled to report its second-quarter results on Thursday. Here is what you need to know:
NET PROFIT: Takeda is expected to post net profit of 50.0 billion yen, equivalent to $326.0 million, for the three months ended Sept. 30, according to a poll of analysts by Visible Alpha. That would compare with net loss of Y48.0 billion in the year-earlier period.
REVENUE: Second-quarter revenue is estimated to have increased 5.7% to Y1.103 trillion, according to the Visible Alpha poll.
The company's shares have risen nearly 5% year to date, closing at Y4,251 on Wednesday.
WHAT TO WATCH:
--The first-quarter's revenue increase was driven by sales growth of several key products. Sales of ulcerative colitis drug Entyvio rose 22% to Y234.4 billion and sales of plasma-derived products gained 30% to Y271.4 billion. Investors will be focusing on the pace of sales growth for these key products.
--For the fiscal year ending March 2025, Takeda has projected revenue to increase 2.0% to Y4.350 trillion but net profit to fall 60% to Y58.00 billion. Investors will be closely watching any changes to the annual guidance management may make.
--The company's operating profit margin deteriorated to 13.8% in its first quarter from 15.9% a year earlier. Investors will be paying attention to margin trends as businesses globally are dealing with relatively high inflation.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
October 30, 2024 06:55 ET (10:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。